Table 1.
Baseline patient characteristics
| Variable | N. (%)a |
|---|---|
| Number of patients | 821 |
| Number of centers | 49 |
|
| |
| Age (years) (median, range) | 41 (18–74) |
| <40 | 366 (45) |
| 40–49 | 220 (27) |
| 50–59 | 167 (20) |
| 60–64 | 48 (6) |
| 65+ | 20 (2) |
|
| |
| Gender | |
| Male | 457 (56) |
| Female | 364 (44) |
|
| |
| Therapy-related diseaseb | 36 (4) |
|
| |
| WBC at diagnosisc | |
| <20 | 411 (50) |
| 20–50 | 138 (17) |
| >50 | 174 (21) |
| Data missing | 98 (12) |
|
| |
| Disease Status at HCT | |
| CR1 | 498 (61) |
| CR2 | 322 (39) |
|
| |
| Duration of 1st CRd | |
| <6 months | 67 (21) |
| 6–12 months | 93 (29) |
| >12 months | 110 (34) |
| Data missing | 52 (16) |
|
| |
| Karnofsky performance score at SCT | |
| ≥90% | 597 (73) |
| <90% | 171 (21) |
| Data missing | 53 (6) |
|
| |
| Donor categorye | |
| MRD | 390 (48) |
| Non-MRD | 431 (52) |
| Well-matched URD | 194 (24) |
| Partially matched URD | 110 (13) |
| Mismatched URD | 110 (13) |
| URD matching unknown | 50 (6) |
| Mismatched relative | 40 (5) |
|
| |
| Graft source | |
| PB | 537 (65) |
| BM | 284 (35) |
|
| |
| Conditioning | |
| Myeloablative | 612 (75) |
| Non-myeloablative/Reduced intensity | 209 (25) |
|
| |
| GVHD prophylaxis | |
| Calcineurin inhibitor-based | 768 (94) |
| T-cell depletion | 32 (4) |
| Other | 21 (3) |
|
| |
| CMV serostatusf | |
| Recipient or donor + | 619 (75) |
|
| |
| Gender matchingg | |
| Female to male | 180 (22) |
| Male to female | 202 (25) |
| Female to female | 161 (20) |
| Male to male | 277 (34) |
|
| |
| Year of HCT (median, range) | 2002 (1999–2004) |
|
| |
| Months of follow-up (median, range) | 61 (3–122) |
a
Percentages may not add to 100 because of rounding
b
Data missing on 4 patients.
c
Units are x109/l.
d
For patients in CR2.
e
Classified according to reference (17).
f
Data missing on 21 patients.
g
Data missing on 3 patients.
WBC, white blood cell count; HCT, allogeneic hematopoietic stem cell transplantation; CR, complete remission; MRD, matched related donor; URD, unrelated donor; PB, peripheral blood; BM, bone marrow; GVHD, graft-versus-host disease; CMV, cytomegalovirus.